Chiesi
As of the edition of 20 October 2026, Chiesi runs 10 drugs, 10 of them marketed; it is on route A at 0 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 10 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Mannitol | none listed | 0 |
| Tobramycin | none listed | 0 |
| Deferiprone | Ends 2028 (exclusivity) | 0 |
| Cangrelor | none listed | 0 |
| Clevidipine | none listed | 8 |
| Nicardipine | none listed | 4 |
| Zileuton | none listed | 1 |
| Poractant alfa | Ended 2011 (computed from the first US licence) | 0 |
| Reteplase | Ended 2008 (computed from the first US licence) | 0 |
| Elapegademase | Ends 2030 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 5 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Chiesi needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.